to the RPL30 promoter reflects the binding of these two proteins to FHL1, suggesting that the binding of IFH1 Inspection of the many isolated IFH1 and CRF1 prey plasmids delineated the regions in IFH1 and CRF1 reand CRF1 to the promoter is FHL1-dependent. To investigate if the binding of IFH1 and CRF1 to the RP gene quired for interaction with FHL1. IFH1 and CRF1 interacted with FHL1 via an internal region common to both promoter is FHL1-dependent, we examined promoter binding of IFH1 and CRF1 in an FHL1 deletion (fhl1⌬) proteins. We refer to this homologous region as the Forkhead-binding (FHB) domain. The FHB domains fall strain. Binding of neither IFH1 nor CRF1 to the RPL30 promoter was detected in the fhl1⌬ strain either treated within amino acids 644-800 of IFH1 (1086 total residues) and amino acids 279-467 of CRF1 (467 total residues).
or untreated with rapamycin, indicating that IFH1 and CRF1 require FHL1 for promoter binding ( Figure 2B ). The two FHB domains display 59% identity over a core Figure 3C ). A crf1⌬ gat1⌬ gln3⌬ strain CRF1 is a negative regulator of RP genes. To determine if CRF1 is a repressor, we examined expression of sevwas generated for this purpose, because the GAT1 and GLN3 transcription factors independently inhibit growth eral RP genes (RPL30, RPL19A, RPL16A, RPL9A, RPS26A, and RPS11A) in wild-type and crf1⌬ cells upon TOR inactivation and would thus mask a potential rapamycin-resistance phenotype conferred by crf1⌬ treated and untreated with rapamycin. (Figures 5B and 6A) . Thus, upon TOR inactivation, YAK1 phorylated CRF1-FHB ( Figure 6D ). YAK1 KD also failed to promote nuclear localization of CRF1 in rapamycinappears to activate CRF1 and, thereby, to negatively regulate RP gene expression. treated cells (data not shown), suggesting that YAK1 kinase activity is required for CRF1 regulation. YAK1 To investigate further the control of CRF1 by YAK1, we examined if YAK1 phosphorylates CRF1 in a TORautophosphorylates on one or more tyrosine residues (Moriya et al., 2001), and we also detected rapamycinsensitive manner. CRF1 was immunoprecipitated from rapamycin-treated and -untreated wild-type and yak1⌬ induced YAK1 autophosphorylation on tyrosine residues ( Figure 6C ). These results suggest that YAK1 specells, and subsequently probed with antiphosphothreonine antibodies. Threonine-phosphorylated CRF1 was cifically phosphorylates and thereby activates CRF1 directly. Furthermore, the observation that YAK1 autodetected only in rapamycin-treated, wild-type cells (Figure 6B) Tables S1 and S2 (available on Cell plates. website), respectively. All strains from our laboratory are isogenic derivatives of TB50 or JK9-3d. The yeast two-hybrid analysis was performed with strain PJ69-4A (James et al., 1996). Rich medium RNA Isolation and Northern Blot Analysis RNA from cells treated with rapamycin or drug vehicle alone was (YPD) or synthetic medium (SD or SC) were prepared as described previously (Beck et al., 1999; Sherman, 1991) , with the exception that isolated as described previously (Schmitt et al., 1990) . Probe synthesis by PCR using digoxygenin-modified dUTP and subsequent the synthetic media were supplemented with 0.2% yeast extract.
